Gene therapy takes on HIV and cancer in one shot
NCT ID NCT02797470
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a gene therapy approach for people with HIV who also have lymphoma that has returned or not responded to treatment. Researchers take the patient's own stem cells, add anti-HIV genes in the lab, and return them after a stem cell transplant. The goal is to see if this is safe and if the modified cells can resist HIV infection. Only 11 participants are enrolled, so results are very preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- gene-modified stem cells (anti-HIV genes)
- What this could lead to
- If successful, this could point toward a way to make immune cells resistant to HIV, potentially reducing the need for lifelong antiviral drugs.
- What could go wrong
- This is a very early, small study (11 people) focused on safety. The gene therapy may not work as hoped, and there are risks from the stem cell transplant and chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
UCSF Medical Center-Parnassus
San Francisco, California, 94115, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new strategy break the cycle of HIV care dropout?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Smart pill bottles and health coaches team up to tackle HIV in the deep south
- Can one Mega-Dose of an antifungal beat a deadly infection in AIDS patients?
- Can Long-Acting HIV shots outperform daily pills during lymphoma treatment?
- Can a Two-Pronged antibody boost chemo against tough lymphomas?